In 2014, we began supporting the use of bedaquiline in Georgia through the compassionate use mechanism, whereby patients with life-threatening conditions gain access to investigational drugs. The following year, Georgia became one of 17 participating countries in the endTB observational study of bedaquiline and delamanid to find shorter, more tolerable, injection-free treatments for MDR-TB. A total of 297 patients were enrolled in this study. In 2017, the first patient was enrolled in the endTB clinical trial—a randomized trial that followed the endTB study in the search for better MDR-TB treatment.
Today, Georgia is one of only four MDR-TB high-burden countries to have implemented all-oral regimens for more than 95 percent of MDR-TB patients. Please donate to support our work in Georgia and other countries around the world now.
